Barc signs biobanking agreement for HIV vaccine trials
Since October 2008, BARC has performed peripheral blood mononuclear cell (PBMC)-isolation services for the HVTN HIV vaccine trials at various locations in South Africa. Under the new agreement,
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.